IPP Bureau

Lupin receives EIR from FDA for its Aurangabad facility
Lupin receives EIR from FDA for its Aurangabad facility

By IPP Bureau - November 13, 2025

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million
NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million

By IPP Bureau - November 13, 2025

Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex

Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg
Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg

By IPP Bureau - November 13, 2025

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag
Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

By IPP Bureau - November 13, 2025

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities
Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

By IPP Bureau - November 13, 2025

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

Philogen updates on Fibromun clinical study developments
Philogen updates on Fibromun clinical study developments

By IPP Bureau - November 13, 2025

FIBROSARC did not meet its primary PFS endpoint in the final analysi

Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components
Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components

By IPP Bureau - November 13, 2025

The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability

BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”
BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”

By IPP Bureau - November 12, 2025

The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance

Novartis opens radioligand therapy manufacturing facility in California
Novartis opens radioligand therapy manufacturing facility in California

By IPP Bureau - November 12, 2025

New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii

Tata 1mg boosts delivery speed with AI-driven logistics
Tata 1mg boosts delivery speed with AI-driven logistics

By IPP Bureau - November 12, 2025

This partnership has led to a 10% boost in delivery speed

JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr

By IPP Bureau - November 12, 2025

Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore

Moraine appointed as distributor for OTSAW’s Hospital robots in Japan
Moraine appointed as distributor for OTSAW’s Hospital robots in Japan

By IPP Bureau - November 12, 2025

Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

By IPP Bureau - November 12, 2025

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

By IPP Bureau - November 12, 2025

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line

Shilpa Medicare announces positive Phase 3 results for Oeris
Shilpa Medicare announces positive Phase 3 results for Oeris

By IPP Bureau - November 12, 2025

OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days

Latest Stories

Interviews

Packaging